117 related articles for article (PubMed ID: 11172689)
1. Nuclear targeting and retention of anthracycline antitumor drugs in sensitive and resistant tumor cells.
Taatjes DJ; Koch TH
Curr Med Chem; 2001 Jan; 8(1):15-29. PubMed ID: 11172689
[TBL] [Abstract][Full Text] [Related]
2. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines.
Taatjes DJ; Fenick DJ; Koch TH
Chem Res Toxicol; 1999 Jul; 12(7):588-96. PubMed ID: 10409398
[TBL] [Abstract][Full Text] [Related]
3. Epidoxoform: a hydrolytically more stable anthracycline-formaldehyde conjugate toxic to resistant tumor cells.
Taatjes DJ; Fenick DJ; Koch TH
J Med Chem; 1998 Apr; 41(8):1306-14. PubMed ID: 9548820
[TBL] [Abstract][Full Text] [Related]
4. Growth inhibition, nuclear uptake, and retention of anthracycline-formaldehyde conjugates in prostate cancer cells relative to clinical anthracyclines.
Taatjes DJ; Koch TH
Anticancer Res; 1999; 19(2A):1201-8. PubMed ID: 10368676
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of epidoxorubicin-formaldehyde virtual crosslink of DNA and evidence for its formation in human breast-cancer cells.
Podell ER; Harrington DJ; Taatjes DJ; Koch TH
Acta Crystallogr D Biol Crystallogr; 1999 Sep; 55(Pt 9):1516-23. PubMed ID: 10489446
[TBL] [Abstract][Full Text] [Related]
6. Doxoform and Daunoform: anthracycline-formaldehyde conjugates toxic to resistant tumor cells.
Fenick DJ; Taatjes DJ; Koch TH
J Med Chem; 1997 Aug; 40(16):2452-61. PubMed ID: 9258351
[TBL] [Abstract][Full Text] [Related]
7. Mass spectrometric measurement of formaldehyde generated in breast cancer cells upon treatment with anthracycline antitumor drugs.
Kato S; Burke PJ; Fenick DJ; Taatjes DJ; Bierbaum VM; Koch TH
Chem Res Toxicol; 2000 Jun; 13(6):509-16. PubMed ID: 10858324
[TBL] [Abstract][Full Text] [Related]
8. Cytoplasmic localization of anthracycline antitumor drugs conjugated with reduced glutathione: a possible correlation with multidrug resistance mechanisms.
Serafino A; Sinibaldi-Vallebona P; Gaudiano G; Koch TH; Rasi G; Garaci E; Ravagnan G
Anticancer Res; 1998; 18(2A):1159-66. PubMed ID: 9615782
[TBL] [Abstract][Full Text] [Related]
9. Induction of apoptosis in neoplastic cells by anthracycline antitumor drugs: nuclear and cytoplasmic triggering?
Serafino A; Sinibaldi-Vallebona P; Pierimarchi P; Bernard P; Gaudiano G; Massa C; Rasi G; Ranagnan G
Anticancer Res; 1999; 19(3A):1909-18. PubMed ID: 10470135
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin-formaldehyde conjugate, doxoform: induction of apoptosis relative to doxorubicin.
Burke PJ; Koch TH
Anticancer Res; 2001; 21(4A):2753-60. PubMed ID: 11724351
[TBL] [Abstract][Full Text] [Related]
11. Analysis of drug transport kinetics in multidrug-resistant cells: implications for drug action.
Garnier-Suillerot A; Marbeuf-Gueye C; Salerno M; Loetchutinat C; Fokt I; Krawczyk M; Kowalczyk T; Priebe W
Curr Med Chem; 2001 Jan; 8(1):51-64. PubMed ID: 11172692
[TBL] [Abstract][Full Text] [Related]
12. Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells.
Burke PJ; Kalet BT; Koch TH
J Med Chem; 2004 Dec; 47(26):6509-18. PubMed ID: 15588086
[TBL] [Abstract][Full Text] [Related]
13. Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein.
Benderra Z; Trussardi A; Morjani H; Villa AM; Doglia SM; Manfait M
Eur J Cancer; 2000 Feb; 36(3):428-34. PubMed ID: 10708946
[TBL] [Abstract][Full Text] [Related]
14. Lack of glutathione conjugation to adriamycin in human breast cancer MCF-7/DOX cells. Inhibition of glutathione S-transferase p1-1 by glutathione conjugates from anthracyclines.
Gaudiano G; Koch TH; Lo Bello M; Nuccetelli M; Ravagnan G; Serafino A; Sinibaldi-Vallebona P
Biochem Pharmacol; 2000 Dec; 60(12):1915-23. PubMed ID: 11108808
[TBL] [Abstract][Full Text] [Related]
15. A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance.
Bidwell GL; Davis AN; Fokt I; Priebe W; Raucher D
Invest New Drugs; 2007 Aug; 25(4):313-26. PubMed ID: 17483874
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the epidoxorubicin--formaldehyde conjugate, epidoxoform, in a mouse mammary carcinoma model.
Dernell WS; Powers BE; Taatjes DJ; Cogan P; Gaudiano G; Koch TH
Cancer Invest; 2002; 20(5-6):713-24. PubMed ID: 12197227
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic activity, accumulation, and intracellular distribution of anthracycline antibiotics and their conjugates with the epidermal growth factor in sensitive and resistant MCF-7 cells.
Lutsenko SV; Feldman NB; Gumanov SG; Rodina AV; Severin SE
Biochemistry (Mosc); 2000 Nov; 65(11):1299-304. PubMed ID: 11112847
[TBL] [Abstract][Full Text] [Related]
19. Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei.
Capranico G; Riva A; Tinelli S; Dasdia T; Zunino F
Cancer Res; 1987 Jul; 47(14):3752-6. PubMed ID: 3474061
[TBL] [Abstract][Full Text] [Related]
20. Drug sequestration in cytoplasmic organelles does not contribute to the diminished sensitivity of anthracyclines in multidrug resistant K562 cells.
Loetchutinat C; Priebe W; Garnier-Suillerot A
Eur J Biochem; 2001 Aug; 268(16):4459-67. PubMed ID: 11502206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
